Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells

Enenstein, Judy; Waleh, Nahid; Kramer, Randall H.

doi:10.1016/0014-4827(92)90028-7

Cited by 147 publications

(74 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a1b1, a3b1 and a5b1 are expressed at low levels in quiescent vessels but at minimum, a5b1 is upregulated during angiogenesis. 36 VEGF stimulation of endothelial cells induced an increased regulation of expression in the collagen receptors a1b1 and a2b1. Moreover, collagen I ligation of a1b1 and a2b1 is a decisive step in initiating cord formation of endothelial cells.…”

Section: Discussionmentioning

confidence: 95%

DNAzymes to mouse β1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth

et al. 2009

View full text Add to dashboard Cite

Previously, we designed a DNAzyme (b1DE) targeting the human b1 integrin subunit, which efficiently digested the mRNA of the b1 integrin subunit and downregulated b1 integrin expression in endothelial cells. This DNAzyme blocked the adhesion of endothelial cells and abolished their ability to form microcapillary tubes in Matrigel. In our present study, we demonstrate that b1DE effectively inhibited neovascularization in Matrigel plugs (BALB/c mice, n ¼ 20) and solid human carcinoma tumors developed in nude mice (BALB/cA nude (nu-/-)-B6.Cg-Foxn1 nu ) (n ¼ 30) using prostate carcinoma cells PC-3 (n ¼ 15) and colon adenocarcinoma cells CX1.1 (n ¼ 15). When injected intratumorally, it significantly reduced the tumor size and number of microvessels developed by both CX1.1 and PC-3 cells within the 3 weeks of experiment duration. Thus, DNAzymes targeting b1 integrin genes can inhibit multiple key tumorigenic processes in vitro and in vivo and may serve as useful anti-cancer agents.

show abstract

Section: Discussionmentioning

confidence: 95%

DNAzymes to mouse β1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth

et al. 2009

View full text Add to dashboard Cite

show abstract

“…[18][19][20] Dexamethasone is routinely used as an anti-inflammatory supportive drug, particularly when gene therapeutic approaches are combined with chemotherapy. Transcriptional downregulation of CAR expression by dexamethasone in vitro negatively interfered with the efficiency of adenoviral gene transfer in this study.…”

Section: Discussionmentioning

confidence: 99%

“…[13][14][15][16][17] For ovarian cancer cells, we noticed that even cell lines with a high level of CAR expression can be resistant against adenoviral infection due to loss of integrin avb3 expression by transcriptional silencing of the integrin b3 subunit. 17 Integrin subunit expression can be regulated by several fibrogenic and pro-inflammatory cytokines such as TGFb 18,19 or TNFa. 20 Both TGFb and TNFa can be found at high concentrations in human cancer tissues.…”

Section: Introductionmentioning

confidence: 99%

CAR is a cell–cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFα, and TGFβ

Brüning

Runnebaum

2003

Gene Ther

View full text Add to dashboard Cite

“…The net effect of these actions is an accumulation of ECM. Furthermore, TGF-β modulates the expression of integrins, which are cell-surface receptors for ECM components, thereby facilitating cell adhesion and matrix deposition [39,40]. TGF-β also acts on (myo)fibroblasts, which are the main source of the increased ECM deposition in tissue fibrosis: TGF-β is a chemoattractant for fibroblasts [41], stimulates fibroblast proliferation [42], and regulates transdifferentiation of resident kidney cells into myofibroblasts [43].…”

Section: Transforming Growth Factor-betamentioning

confidence: 99%

ECM homeostasis in renal diseases: a genomic approach

Eikmans

Baelde

Heer

et al. 2003

The Journal of Pathology

View full text Add to dashboard Cite

Chronic renal disease is in general histologically accompanied by a vast amount of scar tissue, ie glomerulosclerosis and interstitial fibrosis. Scarring results from excessive accumulation of extracellular matrix (ECM) components, a process driven by a plethora of cytokines and growth factors. Studies in experimental renal disease which target these regulators using gene therapy limit or prevent the development of scarring. This review focuses specifically on the role of transforming growth factor-beta, platelet-derived growth factor, connective tissue growth factor, hepatocyte growth factor, and epidermal growth factor. The results obtained in animal models hold promise for molecular intervention strategies in human renal disease. Microarray technology allows large-scale gene expression profiling in kidney tissue to identify common molecular pathways in a step towards discovery of new drug targets. Molecular techniques are expected to be used for diagnostic and prognostic purposes in nephrological practice to supplement renal biopsy. Several studies already show that molecular techniques might be of use in routine diagnostic practice. Improvement of diagnosis and prediction of outcome in renal patients might lead to more efficient and earlier therapeutic intervention.

show abstract

Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells

Cited by 147 publications

References 27 publications

DNAzymes to mouse β1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth

DNAzymes to mouse β1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth

CAR is a cell–cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFα, and TGFβ

ECM homeostasis in renal diseases: a genomic approach

Contact Info

Product

Resources

About